Three Times More Americans Are Spending $100,000-Plus on Prescription Drugs
Pricey cancer drugs, expensive new cures for hepatitis and made-to-order drugs have driven U.S. prescription costs to new highs for some Americans, according to a report issued Wednesday.
It finds that more than half a million Americans each took home $50,000 or more worth of prescription drugs last year.
And the number of super-high spenders prescribed $100,000 or more worth of medications nearly tripled from 47,000 to 139,000, pharmacy benefits manager Express Scripts says.
These are often very sick people, the report found. "Among patients whose drug costs reached at least $100,000, more than one-third were treated for at least 10 conditions and more than 60 percent were taking at least 10 different prescription medications," the report reads.
For those spending $100,000 or more a year, specialty, made-to-order drugs known as compounded therapies, as well as drugs for hepatitis C and to treat cancer accounted for two-thirds of the costs, Express Scripts found.
The hepatitis C drugs include Gilead Science's Sovaldi, which can cure the liver-destroying virus. Gilead charges $84,000 for the three-month drug course, and argues that it costs less than treating patients for a lifetime of liver disease.
Express Scripts, which has actively fought drug companies over their pricing, has refused to cover Gilead's other expensive hepatitis C drug Harvoni, and instead negotiated a deal with rival drugmaker Abbvie to get its hepatitis C drug Viekira at a discount.
The benefits manager, which covers about 85 million Americans, has also complained about pricey cancer drugs. Bristol-Myers Squibb's melanoma drug Yervoy can keep patients with terminal melanoma alive for a year or longer but it costs $120,000 for a course of treatment.
Patients are almost never bearing these high costs. Insurance plans covered more than 98 percent of the costs for patients whose drugs cost $100,000 or more in 2014. "Across the cost spectrum, patients in 2014 paid an average of 13.5 percent of their total medication costs, down from 14.9 percent in 2013," the report reads.
